Professional Study Report On U.S. Psychedelic Drugs Market Is Expected To Grow At 16.3% In The Forecast Period Of 2020 To 2027||Doughlas pharmaceuticals limited NeuroRX, Inc. Hikma Pharmaceuticals PLC Amneal Pharmaceuticals, LLC. AVADEL PHARMACEUTICALS, P

U.S. Psychedelic Drugs Market 2021 document provides the most up-to-date market insight and analysis. The key players of the market are making moves like product launches, joint ventures, developments, mergers, and acquisitions which is affecting the market and industry as a whole and also affecting the sales, import, export, revenue, and CAGR values. Furthermore, this report attempts to determine the impact of buyers, substitutes, new entrants, competitors, and suppliers on the market. This market report utilizes expertise solutions and potential capabilities that help to grow business and thrive in the market. This industry analysis report has been prepared based on a detailed market analysis with inputs from industry experts. It includes historic data, present market trends, environment, technological innovation, upcoming technologies, and the technical progress in the related industry.

U.S. Psychedelic Drugs Market is forecasted to grow at 16.3% with factors such as increasing prevalence of depression and mental disorders driving the growth of the U.S. psychedelic drugs market

U.S. psychedelic drugs market has shown an increasing prevalence of depression and mental disorders which are increasing demand of psychedelic drugs. Although, regulations imposed on psychedelic drugs restricts the growth of the market.

Get Full PDF Sample Copy of Report (AVAIL UP-TO 30% OFF) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=us-psychedelic-drugs-market

According to Data Bridge Market Research Jazz Pharmaceuticals, Inc. is the leader for U.S. psychedelic drugs market and this company holds estimated market share of approximately 70% to 80% of the market. The market leader Jazz Pharmaceuticals, Inc. accounts an estimated market share of approximately 75.00% in the U.S. Jazz Pharmaceuticals, Inc. is a leader in psychedelic drugs in the U.S. and additionally, the company is continuously involved in the development of new products to increase its portfolio of psychedelic drugs. The psychedelic drugs sales revenue of Jazz Pharmaceuticals, Inc. has increased drastically by 16% to generate sales revenue of USD 1,525.18 million 2019 as compared to 2018.

The psychedelic drugs are used to enhance or change sensory perceptions, energy levels, thought processes, and to facilitate spiritual experiences. Psychedelic drugs can be categorized into dissociative drugs (such as PCP), empathogens and serotonergic (classic hallucinogens) (such as LSD). These drugs are used in the treatment of major depressive disorder, treatment-resistant depression, panic disorder, post-traumatic stress disorder, and addiction among others. Chemical substances that are used in the psychedelic drugs are a group of LSD, and plants. Psychedelic are sourced from synthetic process (human-made) and plants or mushrooms. Psychedelic drugs has various street names such as LSD which are also known as acid, blotter, dots, sugar, trips and window pane; Ketamine are also known as vitamin K, bump, green, K/Special K, purple and super acid; PCP are also known as angel/angel dust, boat/love boat, peace, killer weed, super grass and ozone.

Leading Key Players:

Johnson & Johnson Services, Inc.
Jazz Pharmaceuticals, Inc.
Celon Pharma SA
COMPASS
usonainstitute.org
Develco pharma schweiz ag
Doughlas pharmaceuticals limited
NeuroRX, Inc.
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals, LLC.
AVADEL PHARMACEUTICALS, PLC
Market Segmentation:

U.S. Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Dissociatives, Empathogens, Serotonergic (Classical Psychedelic Drugs) ), Application (Narcolepsy, Treatment-Resistant Depression, Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder, Others), Route of Administration (Oral, Intranasal, Parenteral, Others), Drugs (Gamma Hydroxybutyric Acid (GHB), Ketamine, 3,4-Methylenedioxymethamphetamine (Ecstasy), Psilocybin), End User (Hospitals, Speciality Clinic, Research Organization, Others), Distribution Channel(Hospital Pharmacy, Compounding Pharmacy, Others) – Industry Trends and Forecast to 2027

List of Figures:

FIGURE 1 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 2 U.S. PSYCHEDELIC DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 U.S. PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS

FIGURE 4 U.S. PSYCHEDELIC DRUGS MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS

FIGURE 5 U.S. PSYCHEDELIC DRUGS MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 U.S. PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 U.S. PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 8 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 9 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION AND INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS ARE DRIVING THE U.S. PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 10 SYNTHETIC IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. PSYCHEDELIC DRUGS MARKET IN 2020 & 2027

FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF U.S. PSYCHEDELIC DRUGS MARKET

FIGURE 12 MENTAL ILLNESS AMONG THE U.S. ADULTS IN 2018, BY DEMOGRAPHIC GROUP

FIGURE 13 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS IN 2018, BY DEMOGRAPHIC GROUP:

FIGURE 14 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS IN 2018, BY GENDER :

FIGURE 15 PREVALENCE OF DEPRESSIVE DISORDERS IN 2017

FIGURE 16 PREVALENCE OF ANXIETY DISORDERS IN 2017

FIGURE 17 PREVALENCE OF BIPOLAR DISORDER IN 2017

FIGURE 18 THE RIPPLE EFFECT OF MENTAL ILLNESS

FIGURE 19 MENTAL AND SUBSTANCE USE DISORDERS GLOBALLY IN 2017

FIGURE 20 PREVALENCE OF MENTAL HEALTH DISORDERS BY DISORDER TYPE IN WORLD IN 2017

FIGURE 21 MAGIC MUSHROOMS PRICES FOR RESEARCHERS IN THE U.S.

FIGURE 22 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2019

FIGURE 23 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2019-2027 (USD MILLION)

FIGURE 24 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2020-2027)

FIGURE 25 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE

————–

Get Complete Details with TOC For Free @ https://www.databridgemarketresearch.com/toc/?dbmr=us-psychedelic-drugs-market

U.S. psychedelic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the U.S. psychedelic drugs market.

U.S. Psychedelic Drugs Market, By Source
On the basis of type, the market is segmented into dissociatives, empathogens, and serotonergic (classical psychedelic drugs). The dissociatives segment dominates the psychedelic drugs market as XYREM (sodium oxybate, Jazz Pharmaceuticals Inc.) is the only approved drug of disruptive psychedelics for the treatment of narcolepsy.
On the basis of application, the market is segmented into narcolepsy, treatment-resistant depression, post-traumatic stress disorder (PTSD), major depressive disorder, others. Narcolepsy as a gamma hydroxybutyric acid (GHB) derivative dominates the psychedelic drugs market and primarily uses psychedelic medicine and the drug has been approved for narcolepsy. Due to this reason, the narcolepsy segment dominates the psychedelic drugs market.
On the basis of route of administration, the market is segmented into oral, intranasal, parenteral, others. Oral is dominant in the psychedelic drugs market as Xyrem is the most branded drug available in the market in oral dosage forms. In addition, patient adherence is very important in symptomatic treatment of the disease. Oral administration of the drug is highly convenient for patients as compared to other forms.
On the basis of drugs, the market is segmented into gamma hydroxybutyric acid (GHB), ketamine, 3,4-methylenedioxymethamphetamine (ecstasy), psilocybin. Gamma hydroxybutyric acid (GHB) dominates the psychedelic drugs market as Xyrem is primarily psychedelic drug and falls into this category. For this reason, the gamma hydroxybutyric acid (GHB) segment dominates the psychedelic drugs market.
On the basis of end user, the market is segmented into hospitals, speciality clinic, research organisation, others. Hospitals dominate the psychedelic drugs market due to high patient load and most medicines are given under the supervision of a doctor. For this reason, the hospital segment dominates the psychedelic drugs market.
On the basis of distribution channel, the market is segmented into hospital pharmacy, compounding pharmacy, others. Hospital pharmacy has the largest market share as these medicines treat more number of patients in hospitals, demand for medicines increases in hospital pharmacy.
Table of Content:

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF U.S. PSYCHEDELIC DRUGS MARKET

1.4 LIMITATION

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 GEOGRAPHICAL SCOPE

2.2 YEARS CONSIDERED FOR THE STUDY

2.3 CURRENCY AND PRICING

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 PRODUCTS LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 VENDOR SHARE ANALYSIS

2.9 SECONDARY SOURCES

2.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PRACTICING PSYCHIATRISTS

4.2 PIPELINE PRODUCTS

5 EPIDEMIOLOGY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION

6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS

6.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH

6.2 RESTRAINTS

6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS

6.2.2 HIGH COST OF PSYCHEDELIC DRUG

6.3 OPPORTUNITIES

6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS

6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY

6.4 CHALLENGE

6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS

7 U.S. PSYCHEDELIC DRUGS MARKET, BY SOURCE

7.1 OVERVIEW

7.2 SYNTHETIC

7.3 NATURAL

8 U.S. PSYCHEDELIC DRUGS MARKET, BY TYPE

8.1 OVERVIEW

8.2 DISSOCIATIVE

8.3 EMPATHOGENS

8.4 SEROTONERGIC (CLASSICAL PSYCHEDELIC DRUGS)

9 U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 NARCOLEPSY

9.3 TREATMENT- RESISTANT DEPRESSION (TRD)

9.4 POST-TRAUMATIC STRESS DISORDER (PTSD)

9.5 MAJOR DEPRESSIVE DISORDER

9.6 OTHERS

10 U.S. PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 ORAL

10.3 INTRANASAL

10.4 PARENTERAL

10.5 OTHERS

11 U.S. PSYCHEDELIC DRUGS MARKET, BY DRUGS

11.1 OVERVIEW

11.2 GAMMA-HYDROXYBUTYRIC ACID (GHB)

11.3 KETAMINE

11.4 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY)

11.5 PSILOCYBIN

12 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITAL

12.3 SPECIALTY CLINICS

12.4 RESEARCH ORGANISATION

12.5 OTHERS

13 U.S. PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 HOSPITAL PHARMACY

13.3 COMPOUNDING PHARMACY

13.4 OTHERS

14 U.S. PSYCHEDELIC DRUGS MARKET, COMPANY LANDSCAPE

15 COMPANY PROFILE

15.1 JAZZ PHARMACEUTICALS, INC.

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 PIPELINE PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.2 JOHNSON & JOHNSON SERVICES, INC.

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 PRODUCT PORTFOLIO

15.2.4 RECENT DEVELOPMENTS

16 POTENTIAL PLAYERS PROFILE

16.1 AVADEL PHARMACEUTICALS, PLC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 PIPELINE PORTFOLIO

16.1.4 RECENT DEVELOPMENT

16.2 AMNEAL PHARMACEUTICALS LLC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 PIPELINE PORTFOLIO

16.2.4 RECENT DEVELOPMENT

16.3 CELON PHARMA SA

16.3.1 COMPANY SNAPSHOT

16.3.2 PIPELINE PORTFOLIO

16.3.3 RECENT DEVELOPMENT

16.4 COMPASS

16.4.1 COMPANY SNAPSHOT

16.4.2 PIPELINE PORTFOLIO

16.4.3 RECENT DEVELOPMENTS

16.5 DEVELCO PHARMA SCHWEIZ AG

16.5.1 COMPANY SNAPSHOT

16.5.2 PIPELINE PORTFOLIO

16.5.3 RECENT DEVELOPMENT

16.6 DOUGHLAS PHARMACEUTICALS LIMITED

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 HIKMA PHARMACEUTICALS PLC

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENTS

16.8 NEURORX, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENTS

16.9 USONAINSTITUTE.ORG

16.9.1 INSTITUTE SNAPSHOT

16.9.2 PIPELINE PORTFOLIO

16.9.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORT

Region & Countries (Customizable):

North America (Canada, United States & Mexico)
Europe (Germany, the United Kingdom, Benelux, France, Russia & Italy)
Asia-Pacific (Japan, South Korea, China, India & Southeast Asia)
South America (Argentina, Brazil, Peru, Colombia, Etc.)
Middle East & Africa (United Arab Emirates, Egypt, Saudi Arabia, Nigeria & South Africa)
More Information Related to TOC, Tables, and Figures Can Be Provided

No. of Microalgae Market Report Pages: 350
No of Tables: 220
No of Figures: 60
Coronavirus can influence the worldwide economy in three principal ways: by straightforwardly influencing creation and request, by making store network and market disturbance, and by its monetary effect on firms and monetary business sectors. The episode of COVID-19 has welcomed impacts on numerous viewpoints, similar to flight undoings travel boycotts and isolates cafés shut all indoor occasions confined more than forty nations highly sensitive situation proclaimed monstrous easing back of the Vaccine market unpredictability falling business certainty, developing frenzy among the populace, and vulnerability about future.

Covid-19 Impact Analysis @ https://www.databridgemarketresearch.com/covid-19-impact/us-psychedelic-drugs-market

Advantages of Buying the Report:

Our report is additionally known for its information exactness and granular market investigation

A total image of the serious situation of the at-home testing units market is portrayed by this report.

The broad range of investigation in regards to the significant headways

It likewise gives a total evaluation of things to come market and the changing business sector situation.

Study the market techniques that are being received by your rivals and driving associations.

Note: If You Have Any Special Requirements, Please Let Us Know And We Will Offer You The Report As You Want. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-
Data Bridge Market research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

About Us:
Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies ly and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others. We provide a variety of services such as market verified industry reports, technology trend analysis, Formative market research, strategic consulting, vendor analysis, production and demand analysis, consumer impact studies among many others.

This release was published on openPR.